Radiotherapy: Encouraging early data for SBRT in prostate cancer

Nature Reviews Urology

Volumn 6, Issue 9, 2009, Pages 478-479

  Abdel Wahab, May ^a   Pollack, Alan ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RECTUM DISEASE; STEREOTACTIC BODY RADIATION THERAPY; URINARY DYSFUNCTION;

DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOSURGERY;

EID: 70349105079     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2009.166     Document Type: Article

References (10)

1. Madsen, B. L. et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results. Int. J. Radiat. Oncol. Biol. Phys. 67, 1099-1105 (2007).
2. King, C. R. et al. Stereotactic body radiotherapy for localized prostate cancer: Interim results of a prospective phase ii clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 73, 1043-1048 (2009).
3. Brenner, D. J. & Hall, E. J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int. J. Radiat. Biol. Phys. 43, 1095-1101 (1999).
4. Dasu, A. Is the α/β ratio for prostate tumors low enough to be used safely in clinical trials? Clin. Oncol. (R. Coll. Radiol. 19 289-301 (2007).
5. Ritter, M. A., Forman, J. D. & Petereit, D. G. Dose-per-fraction escalation for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 66 (Suppl. 1), S11 (2006).
6. Dearnaley, D. P., Syndikus, I. & Norman, A. R. Conventional or hypofractionated high dose intensity modulated radiotherapy in prostate cancer: Preliminary report on acute and late toxicity. Presented at The Prostate Cancer Symposium - a Multidisciplinary Approach. Orlando, FL, February 22-24 (2007).
7. Pollack, A., Hanlon, A. L. & Horowitz, E. M. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int. J. Radiat. Oncol. Biol. Phys. 64, 518-526 (2006).
8. Galalae, R. M. et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 1048-1055 (2004).
9. Demanes, D. J., Rodriguez, R. R., Schour, L., Brandt, D. & Altieri, G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10.year results. Int. J. Radiat. Oncol. Biol. Phys. 61, 1306-1316 (2005).
10. Yoshioka, Y. et al. High-dose-rate brachytherapy as monotherapy for localized prostate cancer: A retrospective analysis with special focus on tolerance and chronic toxicity. Int. J. Radiat. Oncol. Biol. Phys. 56, 213-220 (2003).